Evidence map›Paper›PMID 41321892›Full record

ArticleClinical case reports2025

Hepatoid Carcinoma of the Ovary: Case Report, Clinical Management, and Insights From Literature Review.

Nan Zhang, Zhilan Liu, Dengfeng Cao, Weihua Lou

Abstract read
In one paragraph

Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nan ZhangDepartment of Obstetrics and Gynecology, School of Medicine, Renji Hospital Shanghai Jiao Tong University Shanghai People's Republic of China.ORCID https://orcid.org/0000-0002-8996-6105
Zhilan LiuDepartment of Obstetrics and Gynecology, School of Medicine, Renji Hospital Shanghai Jiao Tong University Shanghai People's Republic of China.
Dengfeng CaoDepartment of Pathology, School of Medicine, Renji Hospital Shanghai Jiao Tong University Shanghai People's Republic of China.
Weihua LouDepartment of Obstetrics and Gynecology, School of Medicine, Renji Hospital Shanghai Jiao Tong University Shanghai People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatoid carcinoma of the ovary (HCO) is an exceedingly rare epithelial ovarian malignancy demonstrating hepatocellular differentiation and marked serum AFP elevation. Due to its rarity, existing literature remains limited, and optimal management strategies remain undefined. Emerging evidence highlights the urgent need for improved recognition of HCO among clinicians and pathologists to enable early diagnosis and inform optimal treatment. In this study, we present a case of HCO from our institution and integrate this with a synthesis of recent advances in the field. This article aims to provide a comprehensive overview of HCO, with the goal of improving clinical awareness and guiding future research directions.

Indexed as

diagnosishepatoid carcinoma of the ovarymolecular mechanismspathological featurestherapy

Identifiers

PMID41321892
PMCPMC12664102

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.